Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PUCQ | ISIN: KYG0519B1023 | Ticker-Symbol: 36X
Frankfurt
06.06.25 | 09:59
6,100 Euro
+0,83 % +0,050
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCENTAGE PHARMA GROUP INTERNATIONAL Chart 1 Jahr
5-Tage-Chart
ASCENTAGE PHARMA GROUP INTERNATIONAL 5-Tage-Chart
RealtimeGeldBriefZeit
6,1006,30006.06.

Aktuelle News zur ASCENTAGE PHARMA GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer-
DiASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report1
DiASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors37ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers...
► Artikel lesen
23.05.ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 202546ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers...
► Artikel lesen
23.05.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING AN ORAL ...2
20.05.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer-
19.05.ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2025-
30.04.ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING-
ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln
30.04.ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - (1) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; (2) PROPOSED AMENDMENTS TO THE 2022 RSU SCHEME; (3) PROPOSED ...-
30.04.ASCENTAGE-B (06855): SECOND PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025-
29.04.AACR 2025: Quintet of investigational oncological drugs puts Ascentage on positive ascent-
28.04.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer1
28.04.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM FIVE PRECLINICAL STUDIES AT 2025 AMERICAN ASSOCIATION OF CANCER RESEARCH ...2
28.04.ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined ...1
24.04.ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin2
24.04.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING ORAL PRESENTATION ...1
21.04.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer1
21.04.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX AND OLVEREMBATINIB IN CHINESE SOCIETY OF CLINICAL ONCOLOGY ...1
21.04.ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines641ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing...
► Artikel lesen
16.04.ASCENTAGE PHARMA GROUP INTERNATIONAL - 20-F, Annual and transition report of foreign private issuers1
Weiter >>
85 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1